Protocol Ledger

NCT04419519 · Phase II · ACTIVE NOT RECRUITING

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Interventional Phase II clinical trial protocol NCT04419519 sponsored by Memorial Sloan Kettering Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-13 Enrollment: 81 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04419519
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)81 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04419519
Protocol FieldVerified Registry Value
NCT IdentifierNCT04419519
Consolidated Lead SponsorMemorial Sloan Kettering Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment81 participants (ACTUAL)
Registered Start Date2020-05-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04419519
Hospital Research SiteLocationSite Profile
Memorial Sloan Kettering Cancer CenterNew York, NYOpen Hospital Dossier ->
Columbia University Irving Medical CenterNew York, NYOpen Hospital Dossier ->
University of WashingtonSeattle, WAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI